Fennec: Operational Challenges Persist Despite Improved Financial Position [Seeking Alpha]
Fennec Pharmaceuticals Inc. (FENC)
Last fennec pharmaceuticals inc. earnings: 11/12 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.fennecpharma.com/investor-relations
Company Research
Source: Seeking Alpha
Follow Summary Fennec Pharmaceuticals markets Pedmark to reduce cisplatin-induced ototoxicity in pediatric patients but faces challenges in adoption. FENC has missed financial projections, with revenues below estimates and declining cash flow. A partnership with Norgine provided a welcome boost to Fennec's financial situation. Treatment guideline updates and FDA warnings are expected to accelerate Pedmark's market uptake. I recommend holding FENC stock for now, awaiting positive earnings and reduced risks before considering a buy. Klaus Vedfelt Fennec's Pedmark Struggles: Financial Projections Missed Amid Slow Market Adoption Fennec Pharmaceuticals NASDAQ: FENC TSX: FRX:CA ) markets Pedmark to reduce the risk of ototoxicity associated with cisplatin in pediatric patients. My last article on Fennec was This article was written by Stephen Ayers 7.34K Follower s Follow I'm a biotech and healthcare investment analyst with several years of clinical experience a
Show less
Read more
Impact Snapshot
Event Time:
FENC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FENC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FENC alerts
High impacting Fennec Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
FENC
News
- The past three years for Fennec Pharmaceuticals (NASDAQ:FENC) investors has not been profitable [Yahoo! Finance]Yahoo! Finance
- Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Fennec Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswire
- Fennec Pharmaceuticals Inc (NASDAQ: FENC) had its price target lowered by analysts at HC Wainwright from $15.00 to $13.00. They now have a "buy" rating on the stock.MarketBeat
FENC
Earnings
- 8/13/24 - Miss
FENC
Sec Filings
- 10/10/24 - Form 4
- 10/1/24 - Form 4
- 10/1/24 - Form 4
- FENC's page on the SEC website